Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAD Study of Vemircopan in Healthy Volunteers
NCT05047458Phase 1Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Nov 2017
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of vemircopan in paroxysmal nocturnal hemoglobinuria (PNH) (3 cohorts), sponsored by Alexion Pharmaceuticals. Primary endpoints: Number Of Participants Experiencing Serious Adverse Events, Number Of Participants Experiencing Grade 3 Or 4 Adverse Events and 3 more. Started Nov 2017; status: completed.
02
Drugs
vemircopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT05047458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05047458.